ICER-ing on the disparity cake: assessment of barriers to fair prescription drug access in the USA

The first annual “Barriers to Fair Access” assessment of prescription drug coverage policies has been released by the Institute for Clinical and Economic Review (ICER; MA, USA). The report assesses 15 of the most widely available prescription medications in the USA in order to determine consistency with 28 drugs deemed fairly priced. Real-world data (RWD) from MMIT’s (PA, USA) market access Analytics solution was used, evaluating the coverage policies of the largest commercial payers in the USA, including CVS Health (CT, USA), Cigna Health Plans (CT, USA), Highmark (PA, USA) and more. ICER analyzed the payer policies with fair access criteria...